{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T02:43:34Z","timestamp":1782701014976,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. Here, we observe a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 do not lose weight compared to control animals. In contrast to control animals, the lungs of vaccinated animals do not show any gross lesions. Minimal to no viral subgenomic RNA (sgRNA) and no infectious virus can be detected in lungs of vaccinated animals. Histopathological evaluation shows extensive pulmonary pathology caused by B.1.1.7 or B.1.351 replication in the control animals, but none in the vaccinated animals. These data demonstrate the effectiveness of the ChAdOx1 nCoV-19 vaccine against clinical disease caused by B.1.1.7 or B.1.351 VOCs.<\/jats:p>","DOI":"10.1038\/s41467-021-26178-y","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T06:25:59Z","timestamp":1633587959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7"],"prefix":"10.1038","volume":"12","author":[{"given":"Robert J.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-6359","authenticated-orcid":false,"given":"Neeltje","family":"van Doremalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle R.","family":"Adney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude Kwe","family":"Yinda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia R.","family":"Port","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2376-2633","authenticated-orcid":false,"given":"Myndi G.","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandi N.","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Barbian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Anzick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Ricklefs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Saturday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-7758","authenticated-orcid":false,"given":"Emmie","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6823-9750","authenticated-orcid":false,"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7711-897X","authenticated-orcid":false,"given":"Teresa","family":"Lambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-3196","authenticated-orcid":false,"given":"Vincent J.","family":"Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"26178_CR1","unstructured":"Chand, M. et al. Investigation of Novel SARS-COV-2 variant Variant of Concern 202012\/01 https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/959361\/Technical_Briefing_VOC202012-2_Briefing_2.pdf (2020)."},{"key":"26178_CR2","doi-asserted-by":"publisher","unstructured":"Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science https:\/\/doi.org\/10.1126\/science.abg3055 (2021).","DOI":"10.1126\/science.abg3055"},{"key":"26178_CR3","doi-asserted-by":"publisher","unstructured":"Tegally, H. et al. Emergence And Rapid Spread of a New Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Lineage with Multiple Spike Mutations in South Africa. https:\/\/doi.org\/10.1101\/2020.12.21.20248640 (2020).","DOI":"10.1101\/2020.12.21.20248640"},{"key":"26178_CR4","doi-asserted-by":"publisher","unstructured":"van Doremalen, N. et al. Intranasal ChAdOx1 nCoV-19\/AZD1222 Vaccination Reduces Shedding of SARS-CoV-2 D614G in Rhesus Macaques. https:\/\/doi.org\/10.1101\/2021.01.09.426058 (2021).","DOI":"10.1101\/2021.01.09.426058"},{"key":"26178_CR5","doi-asserted-by":"publisher","unstructured":"Port, J. R. et al. SARS-CoV-2 Disease Severity and Transmission Efficiency is Increased for Airborne But Not Fomite Exposure in Syrian Hamsters.https:\/\/doi.org\/10.1101\/2020.12.28.424565 (2020).","DOI":"10.1101\/2020.12.28.424565"},{"key":"26178_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","volume":"586","author":"C Mu\u00f1oz-Fontela","year":"2020","unstructured":"Mu\u00f1oz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509\u2013515 (2020).","journal-title":"Nature"},{"key":"26178_CR7","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1038\/s41591-020-1070-6","volume":"26","author":"LH Tostanoski","year":"2020","unstructured":"Tostanoski, L. H. et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat. Med 26, 1694\u20131700 (2020).","journal-title":"Nat. Med"},{"key":"26178_CR8","doi-asserted-by":"publisher","unstructured":"Meyer, M. et al. mRNA-1273 Efficacy in a Severe COVID-19 Model: Attenuated Activation of Pulmonary Immune Cells After Challenge. https:\/\/doi.org\/10.1101\/2021.01.25.428136 (2021).","DOI":"10.1101\/2021.01.25.428136"},{"key":"26178_CR9","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum \u2014 preliminary report. N. Engl. J Med. https:\/\/doi.org\/10.1056\/NEJMc2102017 (2021).","DOI":"10.1056\/NEJMc2102017"},{"key":"26178_CR10","doi-asserted-by":"publisher","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell S0092867421002269 https:\/\/doi.org\/10.1016\/j.cell.2021.02.037 (2021).","DOI":"10.1016\/j.cell.2021.02.037"},{"key":"26178_CR11","doi-asserted-by":"publisher","unstructured":"Planas, D. et al. Sensitivity of Infectious SARS-CoV-2 B.1.1.7 and B.1.351 Variants to Neutralizing Antibodies. https:\/\/doi.org\/10.1101\/2021.02.12.430472 (2021).","DOI":"10.1101\/2021.02.12.430472"},{"key":"26178_CR12","doi-asserted-by":"publisher","unstructured":"Wang, P. et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. https:\/\/doi.org\/10.1101\/2021.01.25.428137 (2021).","DOI":"10.1101\/2021.01.25.428137"},{"key":"26178_CR13","doi-asserted-by":"publisher","unstructured":"Wu, K. et al. mRNA-1273 Vaccine Induces Neutralizing Antibodies Against Spike Mutants From Global SARS-CoV-2 Variants. https:\/\/doi.org\/10.1101\/2021.01.25.427948 (2021).","DOI":"10.1101\/2021.01.25.427948"},{"key":"26178_CR14","doi-asserted-by":"publisher","unstructured":"Xie, X. et al. Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01270-4 (2021).","DOI":"10.1038\/s41591-021-01270-4"},{"key":"26178_CR15","doi-asserted-by":"publisher","unstructured":"Emary, K. R. W. et al. Efficacy of ChAdOx1 nCoV-19\/AZD1222 vaccine against SARS-CoV-2 VOC (B.1.1.7). SSRN (2021) https:\/\/doi.org\/10.2139\/ssrn.3779160 (2021).","DOI":"10.2139\/ssrn.3779160"},{"key":"26178_CR16","doi-asserted-by":"publisher","unstructured":"Hyams, C. et al. Assessing the effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination in prevention of hospitalisations in elderly and frail adults: a single centre test negative case-control study. Lancet https:\/\/doi.org\/10.2139\/ssrn.3796835 (2021).","DOI":"10.2139\/ssrn.3796835"},{"key":"26178_CR17","doi-asserted-by":"publisher","unstructured":"Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 From Neutralization By Convalescent Plasma. https:\/\/doi.org\/10.1101\/2021.01.26.21250224 (2021).","DOI":"10.1101\/2021.01.26.21250224"},{"key":"26178_CR18","doi-asserted-by":"publisher","unstructured":"Greaney, A. J. et al. Comprehensive mapping of Mutations to the SARS-CoV-2 Receptor-Binding Domain That Affect Recognition By Polyclonal Human Serum Antibodies. https:\/\/doi.org\/10.1101\/2020.12.31.425021 (2021) .","DOI":"10.1101\/2020.12.31.425021"},{"key":"26178_CR19","doi-asserted-by":"publisher","unstructured":"Madhi, S. A. et al. Safety and Efficacy of The ChAdOx1 nCoV-19 (AZD1222) Covid-19 Vaccine Against the B.1.351 Variant in South Africa. https:\/\/doi.org\/10.1101\/2021.02.10.21251247 (2021).","DOI":"10.1101\/2021.02.10.21251247"},{"key":"26178_CR20","unstructured":"Janssen. Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum. https:\/\/www.fda.gov\/media\/146338\/download (2021)."},{"key":"26178_CR21","doi-asserted-by":"publisher","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature https:\/\/doi.org\/10.1038\/s41586-020-03041-6 (2020).","DOI":"10.1038\/s41586-020-03041-6"},{"key":"26178_CR22","doi-asserted-by":"crossref","unstructured":"the Oxford COVID Vaccine Trial Group et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1\/2 clinical trial. Nat. Med. 27, 270\u2013278 (2021).","DOI":"10.1038\/s41591-020-01194-5"},{"key":"26178_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"26178_CR24","doi-asserted-by":"publisher","unstructured":"Tarke, A. et al. Negligible impact SARS-CoV-2 Var. CD4 + CD8 + T cell reactivity COVID-19 exposed donors vaccinees. Cell. Rep. Med. https:\/\/doi.org\/10.1101\/2021.02.27.433180 (2021).","DOI":"10.1101\/2021.02.27.433180"},{"key":"26178_CR25","doi-asserted-by":"publisher","unstructured":"Bricker, T. L. et al. A Single Intranasal or Intramuscular Immunization With Chimpanzee Adenovirus Vectored SARS-CoV-2 Vaccine Protects Against Pneumonia in Hamsters. https:\/\/doi.org\/10.1101\/2020.12.02.408823 (2020).","DOI":"10.1101\/2020.12.02.408823"},{"key":"26178_CR26","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","volume":"586","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578\u2013582 (2020).","journal-title":"Nature"},{"key":"26178_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R W\u00f6lfel","year":"2020","unstructured":"W\u00f6lfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465\u2013469 (2020).","journal-title":"Nature"},{"key":"26178_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet j. 17, 10 (2011).","journal-title":"EMBnet j."},{"key":"26178_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357\u2013359 (2012).","journal-title":"Nat. Methods"},{"key":"26178_CR30","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"26178_CR31","doi-asserted-by":"publisher","unstructured":"Avanzato, V. A. et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell https:\/\/doi.org\/10.1016\/j.cell.2020.10.049 (2020).","DOI":"10.1016\/j.cell.2020.10.049"},{"key":"26178_CR32","doi-asserted-by":"publisher","unstructured":"Stadlbauer, D. et al. SARS\u2010CoV\u20102 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr. Protoc. Microbiol. https:\/\/doi.org\/10.1002\/cpmc.100 (2020).","DOI":"10.1002\/cpmc.100"},{"key":"26178_CR33","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"26178_CR34","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","volume":"26","author":"F Amanat","year":"2020","unstructured":"Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033\u20131036 (2020).","journal-title":"Nat. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26178-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:53:50Z","timestamp":1669978430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26178-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26178"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26178-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.11.435000","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,7]]},"assertion":[{"value":"28 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.C.G. is a board member of Vaccitech and named as an inventor on a patent covering the use of ChAdOx1-vector-based vaccines and a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). T.L. is named as an inventor on a patent application covering a SARS-CoV-2 (nCoV-19) vaccine (UK patent application no. 2003670.3). The University of Oxford and Vaccitech, having joint rights in the vaccine, entered into a partnership with AstraZeneca in April 2020 for further development, large-scale manufacture, and global supply of the vaccine. Equitable access to the vaccine is a key component of the partnership. Neither Oxford University nor Vaccitech will receive any royalties during the pandemic period or from any sales of the vaccine in developing countries. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5868"}}